BeOne Medicines AG (ONC) is in Healthcare, Biotechnology, based in Switzerland, listed on NasdaqGS. Market cap 39.83B USD. 52-week range 253.95 to 385.22 USD. Trailing P/E 62.6. Data as of 2026-10-09.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with ...